GAMMA Investing LLC Increases Stock Holdings in Organon & Co. $OGN

GAMMA Investing LLC increased its holdings in Organon & Co. (NYSE:OGN) by 22.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,645 shares of the company’s stock after purchasing an additional 1,034 shares during the period. GAMMA Investing LLC’s holdings in Organon & Co. were worth $55,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. lifted its holdings in Organon & Co. by 17.6% in the 1st quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company’s stock worth $114,000 after purchasing an additional 1,145 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Organon & Co. by 1.5% in the 1st quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company’s stock worth $1,215,000 after purchasing an additional 1,200 shares in the last quarter. Xponance Inc. lifted its holdings in Organon & Co. by 15.2% in the 1st quarter. Xponance Inc. now owns 13,828 shares of the company’s stock worth $206,000 after purchasing an additional 1,823 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Organon & Co. by 6.5% in the 1st quarter. Brown Advisory Inc. now owns 30,174 shares of the company’s stock worth $449,000 after purchasing an additional 1,835 shares in the last quarter. Finally, M&T Bank Corp increased its stake in Organon & Co. by 3.4% in the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company’s stock worth $833,000 after acquiring an additional 1,854 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

Shares of Organon & Co. stock opened at $11.03 on Friday. The stock’s fifty day moving average is $9.86 and its two-hundred day moving average is $10.41. The company has a market capitalization of $2.87 billion, a PE ratio of 4.10, a price-to-earnings-growth ratio of 1.00 and a beta of 0.63. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $19.05.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.94 by $0.06. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.Organon & Co.’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.’s dividend payout ratio is 2.97%.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research note on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.